Welcome to Bio-Angle Vacs
Company
BIO-ANGLE VACS SDN BHD (“BAV” or the “Company”), founded in 2013, is a global and Bionexus status company based in Kuala Lumpur, Malaysia which is the only company globally that principally develops, manufactures and distributes intranasal livestock vaccines to small and large-scale livestock farming owners worldwide. BAV works together with Universiti Putra Malaysia (UPM) , Malaysian Genome and Vaccine Institute (MGVI) and other research institutions to develop solutions for problems relating to the health and disease prevention for livestock.
Our Credo ‘Innovative Vaccine for the Future’, entitles BAV to join the super league of unicorn companies by year 2026. Our mission is to shape the future by shifting the delivery method of the vaccination process by improving the quality, safety and the efficacy of the product. BAV’s continuous R&D program will ensure that it will constantly be the 1st in innovation and development of premium product that is friendly to the user and environment.
For now, BAV has secured few on-going business deals with our local current clients whereas the international business deals shall be closed upon the completion of our proposed GMP facilities. BAV also has some potential clients in the pipeline who are keen to purchase our products.
BAV has already signed a Sale and Purchase Agreement with 5 overseas companies to market 220,000 bottles of STVac to China, Nigeria, Kenya, the Republic of Uganda and the Republic of Chad. Other markets such as Pakistan, Bangladesh, Mongolia, the Republic of Guinea, Sudan, Kazakhstan and Tanzania are in the process of discussion and will be signed later. The market value of animal vaccines in the world is estimated at around USD 12 billion.
The total population of goats worldwide is 2.2 billion. BAV is targeting 20 million goats equivalent to 1% of the total population which has the potential to generate an income of USD 120 million per year.